Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Klinisk laboratoriemedicin) > (2020-2024) > Recommendations fro...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 11209naa a2201513 4500 | |
001 | oai:gup.ub.gu.se/330064 | |
003 | SwePub | |
008 | 240528s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:153397271 | |
024 | 7 | a https://gup.ub.gu.se/publication/3300642 URI |
024 | 7 | a https://doi.org/10.1093/ejendo/lvad0962 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1533972712 URI |
040 | a (SwePub)gud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Teede, Helena J.4 aut |
245 | 1 0 | a Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome |
264 | 1 | c 2023 |
520 | a Study question: What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? Summary answer: International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. What is known already: The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from 6 continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low-to low-quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus-based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, the evidence quality was low, and evidence-practice gaps persist. Study design, size, and duration: The 2023 International Evidence-based Guideline update re-engaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation, and ultimately recommendation strength, and diversity and inclusion were considered throughout. Participants/materials, setting, and methods: This summary should be read in conjunction with the full guideline for detailed participants and methods. Governance included a 6-continent international advisory and management committee, 5 guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health, and other experts, alongside consumers, project management, evidence synthesis, statisticians, and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and 5 face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across 5 guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council. Main results and the role of chance: The evidence in the assessment and management of PCOS has generally improved in the past 5 years but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpin 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include the following: (1) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm, and inclusion of anti-Müllerian hormone levels as an alternative to ultrasound in adults only; (2) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnoea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; (3) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care, and shared decision-making to improve patient experience, alongside greater research; (4) maintained emphasis on healthy lifestyle, emotional well-being, and quality of life, with awareness and consideration of weight stigma; and (5) emphasizing evidence-based medical therapy and cheaper and safer fertility management. Limitations and reasons for caution: Overall, recommendations are strengthened and evidence is improved but remains generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. Wider implications of the findings: The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input, and consumer preferences. Research recommendations have been generated, and a comprehensive multifaceted dissemination and translation programme supports the guideline with an integrated evaluation programme. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Allmänmedicin0 (SwePub)302242 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex General Practice0 (SwePub)302242 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng |
653 | a assessment | |
653 | a evidence based | |
653 | a GRADE | |
653 | a guideline | |
653 | a management | |
653 | a polycystic ovary syndrome | |
700 | 1 | a Tay, Chau Thien4 aut |
700 | 1 | a Laven, Joop J.E.4 aut |
700 | 1 | a Dokras, Anuja4 aut |
700 | 1 | a Moran, Lisa J.4 aut |
700 | 1 | a Piltonen, Terhi T.4 aut |
700 | 1 | a Costello, Michael F.4 aut |
700 | 1 | a Boivin, Jacky4 aut |
700 | 1 | a Redman, Leanne M.4 aut |
700 | 1 | a Boyle, Jacqueline A.4 aut |
700 | 1 | a Norman, Robert J.4 aut |
700 | 1 | a Mousa, Aya4 aut |
700 | 1 | a Joham, Anju E.4 aut |
700 | 1 | a Arlt, Wiebke4 aut |
700 | 1 | a Azziz, Ricardo4 aut |
700 | 1 | a Balen, Adam4 aut |
700 | 1 | a Bedson, Lisa4 aut |
700 | 1 | a Berry, Lorna4 aut |
700 | 1 | a Boivin, Jacky4 aut |
700 | 1 | a Boyle, Jacqueline4 aut |
700 | 1 | a Brennan, Leah4 aut |
700 | 1 | a Brown, Wendy4 aut |
700 | 1 | a Burgert, Tania4 aut |
700 | 1 | a Busby, Maureen4 aut |
700 | 1 | a Ee, Carolyn4 aut |
700 | 1 | a Garad, Rhonda M.4 aut |
700 | 1 | a Gibson-Helm, Melanie4 aut |
700 | 1 | a Harrison, Cheryce4 aut |
700 | 1 | a Hart, Roger4 aut |
700 | 1 | a Hopkins, Kim4 aut |
700 | 1 | a Hirschberg, Angelica Lindén4 aut |
700 | 1 | a Ho, Tuong4 aut |
700 | 1 | a Hoeger, Kathleen4 aut |
700 | 1 | a Jordan, Cailin4 aut |
700 | 1 | a Legro, Richard S.4 aut |
700 | 1 | a Li, Rong4 aut |
700 | 1 | a Lujan, Marla4 aut |
700 | 1 | a Ma, Ronald4 aut |
700 | 1 | a Mansfield, Darren4 aut |
700 | 1 | a Marsh, Kate4 aut |
700 | 1 | a Mocanu, Edgar4 aut |
700 | 1 | a Mol, Ben4 aut |
700 | 1 | a Mormon, Rachel4 aut |
700 | 1 | a Norman, Robert4 aut |
700 | 1 | a Oberfield, Sharon4 aut |
700 | 1 | a Patel, Malika4 aut |
700 | 1 | a Pattuwage, Loyal4 aut |
700 | 1 | a Peña, Alexia4 aut |
700 | 1 | a Redman, Leanne4 aut |
700 | 1 | a Rombauts, Luk4 aut |
700 | 1 | a Romualdi, Daniela4 aut |
700 | 1 | a Shah, Duru4 aut |
700 | 1 | a Spritzer, Poli Mara4 aut |
700 | 1 | a Stener-Victorin, Elisabet4 aut |
700 | 1 | a Tehrani, Fahimeh Ramezani4 aut |
700 | 1 | a Thangaratinam, Shakila4 aut |
700 | 1 | a Thondan, Mala4 aut |
700 | 1 | a Vanky, Eszter4 aut |
700 | 1 | a Wijeyaratne, Chandrika4 aut |
700 | 1 | a Witchel, Selma4 aut |
700 | 1 | a Yang, Dongzi4 aut |
700 | 1 | a Yildiz, Bulent4 aut |
700 | 1 | a Alesi, Simon4 aut |
700 | 1 | a Alur-Gupta, Snigdha4 aut |
700 | 1 | a Avery, Jodie4 aut |
700 | 1 | a Khomami, Mahnaz Bahri4 aut |
700 | 1 | a Benham, Jamie4 aut |
700 | 1 | a Bidstrup, Hugh4 aut |
700 | 1 | a Chua, Su Jen4 aut |
700 | 1 | a Cooney, Laura4 aut |
700 | 1 | a Coster, Thisara4 aut |
700 | 1 | a Fitz, Victoria4 aut |
700 | 1 | a Flanagan, Madeline4 aut |
700 | 1 | a Forslund, Maria,d 1978u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology4 aut0 (Swepub:gu)xforss |
700 | 1 | a Jiskoot, Geranne4 aut |
700 | 1 | a Kazemi, Maryam4 aut |
700 | 1 | a Kempegowda, Punith4 aut |
700 | 1 | a Louwers, Yvonne4 aut |
700 | 1 | a Melin, Johanna4 aut |
700 | 1 | a Melson, Eka4 aut |
700 | 1 | a Mengistu, Yitayeh Belsti4 aut |
700 | 1 | a Naderpoor, Negar4 aut |
700 | 1 | a Neven, Adriana4 aut |
700 | 1 | a Pastoor, Hester4 aut |
700 | 1 | a Rocha, Thais4 aut |
700 | 1 | a Sabag, Angelo4 aut |
700 | 1 | a Subramanian, Anuradhaa4 aut |
700 | 1 | a Tan, Katrina4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi4 org |
773 | 0 | t European Journal of Endocrinologyg 189q 189x 0804-4643x 1479-683X |
856 | 4 8 | u https://gup.ub.gu.se/publication/330064 |
856 | 4 8 | u https://doi.org/10.1093/ejendo/lvad096 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:153397271 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy